NCT01946399

Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF

Dexamethasone Intravitreal Implant for Retinal Vein Occlusion Associated Macular Edema After Treatment Failure With Anti-VEGF Medications

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Retina Research Institute, LLC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To determine if Ozurdex implant can offer an effective treatment for macular edema associated with retinal vein occlusion when treatment with intravitreal Avastin, Lucentis, or Eylea have not demonstrated a significant response.

Detailed description

To determine whether Ozurdex implant can offer an efficacious alternative for treatment of macular edema in the setting of retinal vein occlusion when treatment with intravitreal bevacizumab (Avastin),ranibizumab (Lucentis), and/or aflibercept (Eylea) have not demonstrated significant response.

Conditions

• Retinal Vein Occlusion (RVO)
• Macular Edema

Interventions

Type	Name	Description
DRUG	Ozurdex implant	Intravitreal injection of Dexamethasone implant

Timeline

• Start date: 2013-09-01
• Primary completion: 2016-09-01
• Completion: 2017-09-01
• First posted: 2013-09-19
• Last updated: 2017-12-02

Locations

1 site across 1 country: United States